Natera, Inc. (NTRA)
NASDAQ: NTRA · Real-Time Price · USD
151.46
-11.11 (-6.83%)
May 9, 2025, 4:00 PM - Market closed
Natera Employees
Natera had 4,434 employees as of December 31, 2024. The number of employees increased by 1,141 or 34.65% compared to the previous year.
Employees
4,434
Change (1Y)
1,141
Growth (1Y)
34.65%
Revenue / Employee
$412,945
Profits / Employee
-$42,797
Market Cap
20.59B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 4,434 | 1,141 | 34.65% |
Dec 31, 2023 | 3,293 | 275 | 9.11% |
Dec 31, 2022 | 3,018 | 348 | 13.03% |
Dec 31, 2021 | 2,670 | 855 | 47.11% |
Dec 31, 2020 | 1,815 | 776 | 74.69% |
Dec 31, 2019 | 1,039 | 64 | 6.56% |
Dec 31, 2018 | 975 | 82 | 9.18% |
Dec 31, 2017 | 893 | 41 | 4.81% |
Dec 31, 2016 | 852 | 136 | 18.99% |
Dec 31, 2015 | 716 | 42 | 6.23% |
Dec 31, 2014 | 674 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
NTRA News
- 19 hours ago - Natera, Inc. (NTRA) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 1 day ago - Natera Reports First Quarter 2025 Financial Results - Business Wire
- 1 day ago - Signatera Data From I-SPY 2 Trial to Be Presented at ESMO Breast Annual Congress - Business Wire
- 2 days ago - Prospera™ Heart Test with DQS Outperforms dd-cfDNA Percentage in Detecting Allograft Rejection, New AJT Publication Shows - Business Wire
- 4 days ago - Largest Sarcoma Study to Date with ctDNA Analysis Demonstrates Excellent Performance for Signatera - Business Wire
- 8 days ago - Natera to Report its First Quarter Results on May 8, 2025 - Business Wire
- 10 days ago - Prospective DEFINE-HT Study Demonstrates that Prospera™ Heart is Predictive of Clinical Outcomes and Outperforms Biopsy in Predicting Graft Dysfunction - Business Wire
- 10 days ago - Baron Health Care Fund Q1 2025 Top Net Purchases And Sales - Seeking Alpha